6 results on '"Ayuk, Francis"'
Search Results
2. Management of Patients Undergoing CAR-T Cell Therapy in Germany.
- Author
-
Penack, Olaf, Dreger, Peter, Ajib, Salem, Ayuk, Francis, Baermann, Ben-Niklas, Bug, Gesine, Kriege, Oliver, Jentzsch, Madlen, Kobbe, Guido, Koenecke, Christian, Lutz, Mathias, Martin, Sonja, Schlegel, Paul-Gerhard, Schroers, Roland, von Tresckow, Bastian, Vucinic, Vladan, Subklewe, Marion, Bethge, Wolfgang, and Wolff, Daniel
- Subjects
- *
STEM cell transplantation , *CELLULAR therapy , *HEMATOPOIETIC stem cell transplantation , *CELL transplantation , *CYTOKINE release syndrome , *NON-Hodgkin's lymphoma - Abstract
Introduction: Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin's lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between centers in the prevention, diagnosis, and management of short- and long-term complications. Methods: To capture the current CAR-T cell management among German centers to determine the medical need and specific areas for future clinical research, the DAG-HSZT (Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy) performed a survey among 26 German CAR-T cell centers. Results: We received answers from 17 centers (65%). The survey documents the relevance of evidence in the CAR-T cell field with a homogeneity of practice in areas with existing clinical evidence. In contrast, in areas with no – or low quality – clinical evidence, we identified significant variety in management in between the centers: management of cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, IgG substitution, autologous stem cell backups, anti-infective prophylaxis, and vaccinations. Conclusion: The results indicate the urgent need for better harmonization of supportive care in CAR-T cell therapies including clinical research to improve clinical outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Allogeneic hematopoetic stem cell transplant for patients with refractory T‐Cell lymphomas.
- Author
-
Massoud, Radwan, Naim, Hassan, Klyuchnikov, Evgeny, Janson, Dietlinde, Wolschke, Christine, Ayuk, Francis, and Kröger, Nicolaus
- Subjects
- *
STEM cell transplantation , *T cells , *LYMPHOMAS , *GRAFT versus host disease , *OVERALL survival , *REFRACTORY materials - Abstract
Objective: Allogeneic stem cell transplantation (allo‐SCT) may have a curative potential due to the graft versus lymphoma effect. In this study, we aimed to compare transplant outcomes between refractory‐T‐NHL (ref‐NHL) and Chemosensitive‐T‐NHL (CS‐T‐NHL). Materials and Methods: We retrospectively reviewed the records of 26 ref‐NHL and 29 CS‐T‐NHL consecutive patients who underwent allo‐SCT at our center and compared the transplant outcomes between the groups. Results: All patients were heavily pretreated with 27% of patients relapsing post‐auto‐SCT and two patients in the ref‐T‐NHL post‐allo‐SCT. Patients were transplanted mainly from unrelated donors. There were no differences in leucocytes and platelet engraftment between the two groups. At 3 years, the relapse incidence was 34% in Ref‐TNHL and 19% in CS‐TNHL (p =.33), with non‐relapse mortality rates of 28% and 22%, respectively (p =.52). Female patients and those with a previous auto‐SCT had lower relapse incidence (p =.045, p =.003). The 3‐year overall survival was 39% in Ref‐TNHL and 56% in CS‐TNHL (p =.15). Trends for improved progression‐free survival (PFS) and graft‐versus‐host disease relapse‐free survival (GRFS) were observed in the CS‐TNHL group (PFS: 60% vs. 30%, p =.075; GRFS: 38% vs. 21%, p =.1). Conclusion: Acknowledging the retrospective nature of our study, our results indicate that allo‐SCT has a curative potential in patients with T‐NHL even in refractory status. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Development and Validation of a Concise Objectifiable Risk Evaluation Score for Non-Relapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation.
- Author
-
Weise, Gunnar, Massoud, Radwan, Krause, Rolf, Heidenreich, Silke, Janson, Dietlinde, Klyuchnikov, Evgeny, Wolschke, Christine, Zeck, Gaby, Kröger, Nicolaus, and Ayuk, Francis
- Subjects
- *
EXPERIMENTAL design , *RESEARCH methodology , *RESEARCH methodology evaluation , *CHI-squared test , *DESCRIPTIVE statistics , *HEMATOPOIETIC stem cell transplantation , *OVERALL survival , *COMORBIDITY - Abstract
Simple Summary: This study aimed to create a simple and reliable tool, the CORE HCT score, to predict the chances of non-relapse mortality (NRM) and overall survival (OS) after allogeneic hematopoietic stem cell transplantation (allo-HCT). Using data from 1120 adult patients who had undergone this procedure at our center between 2013 and 2020, we identified specific patient factors affecting NRM: serum albumin, serum creatinine, serum C-reactive protein, heart and lung function, and age. Factors were weighted according to their impact on NRM. The resulting CORE HCT score grouped patients into low-, medium-, and high-risk categories, showing its effectiveness across different conditions and donor types. Notably, compared with the HCT Comorbidity Index (HCT-CI), the CORE HCT score performed better in predicting NRM and OS. The findings were validated in two independent cohorts, which supports the utility of the CORE HCT score in guiding risk assessment for allo-HCT in adult patients with malignant diseases. We aimed to develop a concise objectifiable risk evaluation (CORE) tool for predicting non-relapse mortality (NRM) and overall survival (OS) after allogeneic hematopoietic stem cell transplantation (allo-HCT). A total of 1120 adult patients who had undergone allo-HCT at our center between 2013 and 2020 were divided into training, first, and second validation cohorts. Objectifiable, patient-related factors impacting NRM in univariate and multivariate analyses were: serum albumin, serum creatinine, serum C-reactive protein (CRP), heart function (LVEF), lung function (VC, FEV1), and patient age. Hazard ratios were assigned points (0–3) based on their impact on NRM and summed to the individual CORE HCT score. The CORE HCT score stratified patients into three distinct low-, intermediate-, and high-risk groups with two-year NRM rates of 9%, 22%, and 46%, respectively, and OS rates of 73%, 55%, and 35%, respectively (p < 0.001). These findings were confirmed in a first and a second recently treated validation cohort. Importantly, the CORE HCT score remained informative across various conditioning intensities, disease-specific subgroups, and donor types, but did not impact relapse incidence. A comparison of CORE HCT vs. HCT Comorbidity Index (HCT-CI) in the second validation cohort revealed better performance of the CORE HCT score with c-statistics for NRM and OS of 0.666 (SE 0.05, p = 0.001) and 0.675 (SE 0.039, p < 0.001) vs. 0.431 (SE 0.057, p = 0.223) and 0.535 (SE 0.042, p = 0.411), respectively. The CORE HCT score is a concise and objectifiable risk evaluation tool for adult patients undergoing allo-HCT for malignant disease. External multicenter validation is underway. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture.
- Author
-
Harfmann, Maraike, Schröder, Tanja, Głów, Dawid, Jung, Maximilian, Uhde, Almut, Kröger, Nicolaus, Horn, Stefan, Riecken, Kristoffer, Fehse, Boris, and Ayuk, Francis A.
- Subjects
- *
IN vitro studies , *CELL culture , *CELL receptors , *MYELOID leukemia , *KILLER cells , *GENE expression , *CELLULAR signal transduction , *CELL proliferation , *RESEARCH funding , *T cells , *CELL surface antigens , *T-cell lymphoma , *IMMUNOTHERAPY , *IMMUNODIAGNOSIS - Abstract
Simple Summary: Chimeric antigen receptors (CARs) are used to recognize highly specific antigens ("mugshots") to target immune effectors ("policemen") against cancer cells. Whereas this new immunotherapy has already set novel standards in the treatment of some specific types of blood cancer, it has not yet been successful with most blood (and solid) cancers for different reasons. In this work, the authors investigated the possibility of using a specific antigen called CD45 as target for CAR therapies. CD45 stands out by being present on all blood cells and therefore represents a promising target in any type of blood cancer. However, immune cells themselves also harbor CD45 at their cell surface, which is expected to lead to either inactivity of the CAR or self-killing of immune cells. To avoid these problems the Hamburg group used a trick—they applied the CRISPR/Cas gene scissors and thus produced CD45-knockout (CD45ko) immune-effector cells. Even though CD45 had been supposed to be important for the functionality of immune-effector cells, the authors observed excellent survival, proliferation and killing activities of their CD45ko CAR cells, independent of the targeted cancer-cell population. Their results thus provide initial proof-of-concept for the potential usefulness of CD45ko/CD45-CAR immune cells to target blood cancer. Background: CAR-T cell therapy has shown impressive results and is now part of standard-of-care treatment of B-lineage malignancies, whereas the treatment of myeloid diseases has been limited by the lack of suitable targets. CD45 is expressed on almost all types of blood cells including myeloid leukemia cells, but not on non-hematopoietic tissue, making it a potential target for CAR-directed therapy. Because of its high expression on T and NK cells, fratricide is expected to hinder CD45CAR-mediated therapy. Due to its important roles in effector cell activation, signal transduction and cytotoxicity, CD45 knockout aimed at preventing fratricide in T and NK cells has been expected to lead to considerable functional impairment. Methods: CD45 knockout was established on T and NK cell lines using CRISPR/Cas9-RNPs and electroporation, and the successful protocol was transferred to primary T cells. A combined protocol was developed enabling CD45 knockout and retroviral transduction with a third-generation CAR targeting CD45 or CD19. The functionality of CD45ko effector cells, CD45ko/CD45CAR-T and CD45ko/CD19CAR-T cells was studied using proliferation as well as short- and long-term cytotoxicity assays. Results: As expected, the introduction of a CD45-CAR into T cells resulted in potent fratricide that can be avoided by CD45 knockout. Unexpectedly, the latter had no negative impact on T- and NK-cell proliferation in vitro. Moreover, CD45ko/CD45CAR-T cells showed potent cytotoxicity against CD45-expressing AML and lymphoma cell lines in short-term and long-term co-culture assays. A pronounced cytotoxicity of CD45ko/CD45CAR-T cells was maintained even after four weeks of culture. In a further setup, we confirmed the conserved functionality of CD45ko cells using a CD19-CAR. Again, the proliferation and cytotoxicity of CD45ko/CD19CAR-T cells showed no differences from those of their CD45-positive counterparts in vitro. Conclusions: We report the efficient production of highly and durably active CD45ko/CAR-T cells. CD45 knockout did not impair the functionality of CAR-T cells in vitro, irrespective of the target antigen. If their activity can be confirmed in vivo, CD45ko/CD45CAR-T cells might, for example, be useful as part of conditioning regimens prior to stem cell transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease.
- Author
-
Bonig, Halvard, Verbeek, Mareike, Herhaus, Peter, Braitsch, Krischan, Beutel, Gernot, Schmid, Christoph, Müller, Nadine, Bug, Gesine, Döring, Michaela, von Stackelberg, Arend, Tischer, Johanna, Ayuk, Francis, Wulf, Gerald, Holtick, Udo, Pfeffermann, Lisa‑Marie, Jahrsdörfer, Bernd, Schrezenmeier, Hubert, Kuci, Selim, Kuci, Zyrafete, and Zens, Anke
- Subjects
- *
GRAFT versus host disease , *STROMAL cells , *ACUTE diseases - Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.